These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 7743524

  • 1. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
    Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP.
    Cancer Res; 1995 May 15; 55(10):2200-5. PubMed ID: 7743524
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
    Montero-Julian FA, Brailly H, Sautès C, Joyeux I, Dorval T, Mosseri V, Yasukawa K, Wijdenes J, Adler A, Gorin I, Fridman WH, Tartour E.
    Clin Cancer Res; 1997 Aug 15; 3(8):1443-51. PubMed ID: 9815830
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
    Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmüller U, Nakajima K, Hirano T, Horn F, Behrmann I.
    Oncogene; 1999 Jun 24; 18(25):3742-53. PubMed ID: 10391682
    [Abstract] [Full Text] [Related]

  • 6. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells.
    Oh JW, Katz A, Harroch S, Eisenbach L, Revel M, Chebath J.
    Oncogene; 1997 Jul 31; 15(5):569-77. PubMed ID: 9247310
    [Abstract] [Full Text] [Related]

  • 7. Selection and characterization of a variant of human melanoma cell line, A375 resistant to growth inhibitory effects of oncostatin M (OM): coresistant to interleukin 6 (IL-6).
    McDonald VL, Dick KO, Malik N, Shoyab M.
    Growth Factors; 1993 Jul 31; 9(3):167-75. PubMed ID: 8274294
    [Abstract] [Full Text] [Related]

  • 8. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130).
    Geisterfer M, Richards CD, Gauldie J.
    Cytokine; 1995 Aug 31; 7(6):503-9. PubMed ID: 8580365
    [Abstract] [Full Text] [Related]

  • 9. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
    Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princler GL, Kung HF.
    J Clin Invest; 1994 Dec 31; 94(6):2317-25. PubMed ID: 7989587
    [Abstract] [Full Text] [Related]

  • 10. Loss of oncostatin M receptor beta in metastatic melanoma cells.
    Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, Godard A, Blanchard F.
    Oncogene; 2007 Feb 08; 26(6):881-92. PubMed ID: 16909117
    [Abstract] [Full Text] [Related]

  • 11. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
    Doucet C, Meazza R, Pottin-Clemenceau C, Scudeletti M, Brouty-Boye D, Ferrini S, Alileche A, Taoufik Y, Jasmin C, Azzarone B, Indiveri F.
    Melanoma Res; 1997 Aug 08; 7 Suppl 2():S7-17. PubMed ID: 9578412
    [Abstract] [Full Text] [Related]

  • 12. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor.
    Hooper WC, Phillips DJ, Evatt BL.
    Thromb Haemost; 1997 May 08; 77(5):1014-9. PubMed ID: 9184420
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A.
    J Pathol; 2008 Dec 08; 216(4):451-9. PubMed ID: 18798220
    [Abstract] [Full Text] [Related]

  • 16. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J, Spence MJ, Wallace PM, Forcier K, Hellström I, Vestal RE.
    Cell Growth Differ; 1997 Jun 08; 8(6):667-76. PubMed ID: 9186000
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-2 enhances the growth of human melanoma cells derived form primary but not from metastatic tumours.
    García-Vázquez MD, Boyano MD, Cañavate ML, Gardeazabal J, de Galdeano AG, López-Michelena T, Ratón JA, Izu R, Díaz-Ramón JL, Díaz-Pérez JL.
    Eur Cytokine Netw; 2000 Dec 08; 11(4):654-61. PubMed ID: 11125310
    [Abstract] [Full Text] [Related]

  • 18. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O.
    Cancer Res; 1995 Feb 01; 55(3):590-6. PubMed ID: 7834629
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors.
    Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A.
    J Immunol; 1991 Jun 01; 146(11):3809-14. PubMed ID: 2033252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.